These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 22237239)

  • 1. A rare complication of pegylated interferon Alfa 2a in a hepatitis C-positive patient on maintenance hemodialysis.
    Satish R; ; Mathew T
    Saudi J Kidney Dis Transpl; 2012 Jan; 23(1):139-42. PubMed ID: 22237239
    [No Abstract]   [Full Text] [Related]  

  • 2. Peripheral nervous system involvement in a haemodialysis patient treated with pegylated interferon.
    Ruiz-Fuentes MC; Rubert-Gómez De Quero A; De Gracia-Guindo C; Galindo-Sacristán P; Osuna-Ortega A
    Nefrologia; 2012; 32(6):863-5. PubMed ID: 23169385
    [No Abstract]   [Full Text] [Related]  

  • 3. Adult respiratory distress syndrome after treatment with pegylated interferon alpha-2a and ribavirin.
    Vartany E; Caldwell CA; Trow TK
    Heart Lung; 2008; 37(2):153-6. PubMed ID: 18371508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of hepatitis C in hemodialysis patients with pegylated interferon alpha-2a as monotherapy.
    Sikole A; Dzekova P; Selja N; Gaseva M; Nikolov IG; Zabzun M; Muharemi S; Asani A; Amitov V; Mena S; Grunevska V; Ivanovski L; Polenakovic M
    Ren Fail; 2007; 29(8):961-6. PubMed ID: 18067041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombotic microangiopathy complicating pegylated interferon treatment of hepatitis C infection.
    Iskander D; Wickremasinghe M; Bain BJ
    Am J Hematol; 2011 Oct; 86(10):859. PubMed ID: 21630311
    [No Abstract]   [Full Text] [Related]  

  • 6. Multicenter study of pegylated interferon α-2a monotherapy for hepatitis C virus-infected patients on hemodialysis: REACH study.
    Kikuchi K; Akiba T; Nitta K; Masakane I; Ando R; Izumi N; Atsukawa M; Yamazaki C; Kato F; Hotta N; Tominaga Y; Orito E; Hora K; Nagasawa M; Kasahara H; Kawaguchi M; Kimura H; Ikebe N; Kawanishi H; Moriishi M; Shigemoto K; Harada T; Hirakata H; Watanabe H; Nosaki T; Tsubouchi H; Imawari M; Akizawa T
    Ther Apher Dial; 2014 Dec; 18(6):603-11. PubMed ID: 25196061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of hepatitis C in patients on renal replacement therapy].
    Tornai I; Mátyus J
    Orv Hetil; 2007 Mar; 148(11):489-94. PubMed ID: 17350920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pegylated interferon alfa-2a monotherapy for hemodialysis patients with acute hepatitis C.
    Liu CH; Liang CC; Liu CJ; Lin JW; Chen SI; Hung PH; Tsai HB; Lai MY; Chen PJ; Chen DS; Kao JH
    Clin Infect Dis; 2010 Sep; 51(5):541-9. PubMed ID: 20645865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Catatonia associated with pegylated interferon-α 2b and ribavirin for hepatitis C.
    Quinn D; Kuchler E; Deming P; Arora S
    Psychosomatics; 2012; 53(4):400-1. PubMed ID: 22748752
    [No Abstract]   [Full Text] [Related]  

  • 10. Generalized interstitial granuloma annulare induced by pegylated interferon-alpha.
    Kluger N; Moguelet P; Chaslin-Ferbus D; Khosrotherani K; Aractingi S
    Dermatology; 2006; 213(3):248-9. PubMed ID: 17033180
    [No Abstract]   [Full Text] [Related]  

  • 11. Development of bronchiolitis obliterans organizing pneumonia during standard treatment of hepatitis C with Peg-IFNα2b.
    Chung E; Park K; Kim JH; Han NI; Lee YS; Bae SH; Park CH
    Korean J Intern Med; 2017 Nov; 32(6):1098-1100. PubMed ID: 28823117
    [No Abstract]   [Full Text] [Related]  

  • 12. Pegylated interferon for the treatment of hepatitis C virus in haemodialysis patients.
    Teta D; Lüscher BL; Gonvers JJ; Francioli P; Phan O; Burnier M
    Nephrol Dial Transplant; 2005 May; 20(5):991-3. PubMed ID: 15741205
    [No Abstract]   [Full Text] [Related]  

  • 13. Erythema gyratum repens induced by pegylated interferon alfa for chronic hepatitis C.
    Rongioletti F; Fausti V; Parodi A
    Arch Dermatol; 2012 Oct; 148(10):1213-4. PubMed ID: 23069974
    [No Abstract]   [Full Text] [Related]  

  • 14. [Healing hepatitis C infections. Pegylated interferon alfa-2a opens new perspectives].
    MMW Fortschr Med; 2003 Jun; 145(26):52-3. PubMed ID: 12916339
    [No Abstract]   [Full Text] [Related]  

  • 15. Pegylated interferon-induced immune-mediated hepatitis post-liver transplantation.
    Kontorinis N; Agarwal K; Elhajj N; Fiel MI; Schiano TD
    Liver Transpl; 2006 May; 12(5):827-30. PubMed ID: 16628699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of pegylated interferon alfa-2b and ribavirin combination therapy versus pegylated interferon monotherapy in hemodialysis patients: a comparison of 2 sequentially treated cohorts.
    Tseng PL; Chen TC; Chien YS; Hung CH; Yen YH; Chang KC; Tsai MC; Lin MT; Lee CT; Shen CH; Hu TH
    Am J Kidney Dis; 2013 Oct; 62(4):789-95. PubMed ID: 23746377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Secondary hemophagocytic syndrome due to Peg-interferon administration].
    Ruiz Ramos J
    Farm Hosp; 2014 Jan; 38(1):73-4. PubMed ID: 24483865
    [No Abstract]   [Full Text] [Related]  

  • 18. Rhabdomyolysis associated with the co-administration of daptomycin and pegylated interferon α-2b and ribavirin in a patient with hepatitis C.
    Colomba C; Rubino R; Siracusa L; Mazzola G; Titone L
    J Antimicrob Chemother; 2012 Jan; 67(1):249-50. PubMed ID: 21965434
    [No Abstract]   [Full Text] [Related]  

  • 19. Pegylated interferon and ribavirin therapy for hepatitis C causing cataract.
    Ku JY; Sharma A
    Clin Exp Ophthalmol; 2009 Sep; 37(7):743-5. PubMed ID: 19788675
    [No Abstract]   [Full Text] [Related]  

  • 20. Fulminant type 1 diabetes caused by peginterferon α-2a therapy in hepatitis C.
    Zheng Y; Wang Z; Xie Z; Dai R; Zhou Z
    J Diabetes; 2018 May; 10(5):419-420. PubMed ID: 29265717
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.